Drug Profile
Research programme: anticancer radioimmunotherapeutics - Nordic Nanovector
Alternative Names: 177Lu-conjugated humanized anti-CD37 antibodyLatest Information Update: 24 Apr 2023
Price :
$50
*
At a glance
- Originator Nordic Nanovector
- Developer Nordic Nanovector; Norwegian Radium Hospital
- Class Antibodies; Drug conjugates; Immunoconjugates; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Non-Hodgkin's lymphoma
Most Recent Events
- 18 Apr 2023 Research programme: anticancer radioimmunotherapeutics - Nordic Nanovector is available for licensing as of 24 Apr 2023. https://www.nordicnanovector.com/
- 06 May 2022 Preclinical development for Non-Hodgkin's lymphoma is ongoing in Norway
- 28 Apr 2022 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in Norway (Parenteral)